Johnson & Johnson (JNJ): FY25 Q4 earnings call, Jan 21, 2026
On its Jan 21, 2026 earnings call (FY25 Q4), Johnson & Johnson said 10 of the 13 words Kalshi and Polymarket listed; Parrot’s count agreed with all 13 settlements. Quotes below are at most 25 words each.
UpdatedMarkets
13 words · 10 settled yes · our count agreed on 13 of 13- Kalshi: company speakers + operator
Kalshi - Polymarket: anyone
Polymarket
backtest The probabilities on settled rows are a walk-forward backtest: the model as of before each event, computed after Parrot went live; they were not published at the time.
| Word | Result | Our count | All speakers | Agrees | Probability | Market |
|---|---|---|---|---|---|---|
| Carvykti | Yes | 6 | 7 | ✓ | 90%transcripts from the transcript model | – |
| Rybrevant | Yes | 3 | 3 | ✓ | 89%transcripts from the transcript model | – |
| Procedure | Yes | 3 | 3 | ✓ | 88%transcripts from the transcript model | – |
| China | Yes | 3 | 3 | ✓ | 86%transcripts from the transcript model | – |
| Ottava | Yes | 3 | 3 | ✓ | 77%transcripts from the transcript model | – |
| Halda Therapeutics | Yes | 3 | 3 | ✓ | 16%transcripts from the transcript model | – |
| Halda Therapeutics / Haida Therapeutics | Yes | 3 | 3 | ✓ | 16%transcripts from the transcript model | – |
| Europe | Yes | 1 | 1 | ✓ | 84%transcripts from the transcript model | – |
| Administration | Yes | 1 | 1 | ✓ | 70%transcripts from the transcript model | – |
| Nipocalimab / Lupus | Yes | 1 | 1 | ✓ | 43%transcripts from the transcript model | – |
| Vaccine | No | 0 | 0 | ✓ | 52%transcripts from the transcript model | – |
| Darzalex Faspro | No | 0 | 0 | ✓ | 23%transcripts from the transcript model | – |
| Trufill | No | 0 | 0 | ✓ | 16%transcripts from the transcript model | – |
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Oct 21, 2026 04:22 UTC.
Transcript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
Where the listed words were said
…over $14 billion, DARZALEX grew an impressive 22% across the full year. Carvicti is the leading CAR T cell therapy in multiple myeloma, with more…
…partially offset by the impact of Part D redesign. In lung cancer, Ribrovant plus Lascluse delivered sales of $216 million and growth of 76.5%, driven…
…at least two Carto updates each year. In surgery, we are reinventing procedures through robotics and digital. This year, we will launch a first-of-its-kind robotics…
…by competitive pressures in energy and endocutters as well as VBP in China across the portfolio. In vision, contact lenses and other products grew 5.3%,…
…and we plan to be a relevant player in robotic surgery with Ottava and also with the launch of Monarch in urology, in which we…
…billion in R&D and M&A, including the acquisitions of Intracellular Therapies and Halda Therapeutics. We also initiated billions of dollars in new state-of-the-art manufacturing facilities…
…approvals addressing larger patient populations are anticipated. And our Q4 acquisition of Halda Therapeutics added a promising clinical-stage treatment for prostate cancer with potential across…
…the markets that matter most, especially here in the US and in Europe. You will have seen that in the fourth quarter, our growth accelerated…
…as the first subcutaneous therapy for EGFR-mutated non-small cell lung cancer, reducing administration time from hours to minutes and improving patient experience. We are making…
…spoken about yet today, but areas such as Sjogren's disease and SLE, lupus, areas of really high unmet medical need. Atopic dermatitis, of which we…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2026-01-21:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2026-01-21:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP